{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:dapiclermin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00103545: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2003)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02306161: Phase 3 Interventional Active, not recruiting Metastatic Ewing Sarcoma
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rolipoltide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02998983: Phase 2 Interventional Completed Neuroblastoma
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:SOFITUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04426201: Phase 2 Interventional Terminated COVID-19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03019627: Phase 2 Interventional Completed Dry Eye
(2017)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
